Press Release - Company Data

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
Posted 2014-05-29 23:43NAI Editing
a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI B

CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
Posted 2014-03-02 23:36NAI Editing
today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose plate

CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
Posted 2014-03-02 23:36NAI Editing
today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose plate

Cell Therapeutics Appoints Karen Ignagni to Board of Directors
Posted 2014-02-02 23:48NAI Editing
today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately. Ms.

Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer
Posted 2014-01-27 23:35NAI Editing
announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio™

Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Posted 2014-01-13 23:40NAI Editing
today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio.

Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
Posted 2014-01-12 23:51NAI Editing
today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI®) and paclitaxel poliglumex (Opaxio™).

Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Posted 2014-01-01 23:36NAI Editing
today announced that it has received notification from the U.S.

Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
Posted 2013-12-17 23:36NAI Editing
today announced that CTI has received the remaining $5 million from Hercules Technology Growth Capital, Inc.

Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI® (pixantrone) in Germany
Posted 2013-12-03 23:30NAI Editing
announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).